CN101993439B - Lamivudine crystal form and preparation method thereof - Google Patents
Lamivudine crystal form and preparation method thereof Download PDFInfo
- Publication number
- CN101993439B CN101993439B CN 201010254731 CN201010254731A CN101993439B CN 101993439 B CN101993439 B CN 101993439B CN 201010254731 CN201010254731 CN 201010254731 CN 201010254731 A CN201010254731 A CN 201010254731A CN 101993439 B CN101993439 B CN 101993439B
- Authority
- CN
- China
- Prior art keywords
- lamivudine
- follows
- crystal
- preparation
- crystal form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to lamivudine crystal form and a preparation method thereof. Under the Cu-Ka radiation, the characteristic peaks of the lamivudine crystal form IV of the invention appear on the crystal X-ray powder diffraction pattern at the following reflection angle 2 theta: 9.7+/-0.2, 10.02+/-0.2, 11.24+/-0.2, 11.52+/-0.2, 12.80+/-0.2 and 13.10+/-0.2.
Description
1, technical field
The invention belongs to medical technical field, be specifically related to lamivudine new crystal and preparation method thereof.
2, background technology
Lamivudine is known compound, and English name Lamivudine claims again 3-TC.The chemical nature of lamivudine is nucleoside analog, and nucleoside analog is structurally simulated the structure of Nucleotide, but does not have the function of Nucleotide.Therefore in the DNA building-up process, nucleoside analog can mix into, but can not synthesize the nucleic acid chains that normal function is arranged, thereby makes the termination that copies of virus.Its mechanism of action is for suppressing viral DNA polymerase and reverse transcriptase activity, and to the synthetic of viral DNA chain with prolong competitive restraining effect.
In recent years, lamivudine was extensively accepted by doctors and patients as a kind of new nucleoside analog, was best, the most representative nucleoside analog of curative effect in the present clinical application.
At present, the existing document that lamivudine is carried out study on the synthesis.Applied for that in China denomination of invention is such as Chinese patent nineteen ninety Canada Bio-chemical pharmacy Corp: the patent of " replacement 1 of antiviral property being arranged, the preparation method of 3-oxygen thia alkane ", this patent were authorized in 1996, and notification number is 1033640C.Canadian Bio-chemical pharmacy Corp had applied in China that denomination of invention was in 1991: the patent of " 1; preparation method of 3-Oxathiolane Nucleoside Analogues "; the method for splitting of the claimed cis lamivudine of this patent, this patent was authorized in 1997, and notification number is 1036196C.Canadian Bio-chemical pharmacy Corp had applied in China that denomination of invention was: the patent of " method of diastereoselective synthesis nucleosides " in 1992, this patent was authorized in 1998, notification number is 1038591C, Canadian Bio-chemical pharmacy Corp had applied in China that denomination of invention was in 1994: the patent of " synthesizing with three-dimensional selection of the nucleoside analog of bicyclic intermediate ", publication number is 1110479A.Nineteen ninety-five, Glan element company applied for that in China denomination of invention is: the patent of " the non-mapping of nucleoside analog is selected synthetic ", publication number is 1149871.
But above-mentioned document does not illustrate the crystal habit of lamivudine.
The raw produce; raw products of existing lamivudine, poor stability, the preparation difficulty of moulding is made in difficult quality control.
The present invention finds unexpectedly, lamivudine is prepared into certain new crystallized form can makes it stable, for this reason, the invention provides the new crystal of two kinds of lamivudines.
3, summary of the invention
The inventor has carried out the experimental study of a large amount of systems to the crystal formation of lamivudine, obtained the new crystal formation of two kinds of lamivudines, i.e. III type crystal formation and IV type crystal formation.
The present invention also provides the preparation method of two kinds of crystal formations of lamivudine.
Lamivudine III crystal formation of the present invention uses the Cu-Ka radiation, and the X-ray powder diffraction that represents with 2 θ angles has characteristic peak 9.5 ± 0.2,10.3 ± 0.2,11.14 ± 0.2,13.08 ± 0.2.
Its infrared analysis data are as follows:
IR(KBr)cm
-1:3417,3359,3232,2925,1644,1613,1493,1403,1356,1289,1197,1108,1053,786
Its fusing point is as follows:
DSC (10 ℃ of heat-up rates/min): a little endothermic melting peak occurs at 121.9 ℃, a sharp-pointed endothermic melting peak occurs again at 176.3 ℃.
Concrete X-ray powder diffraction data are as follows:
Powder X-ray-diffraction: Cu-Ka radiation, the 2 θ angles of this product, spacing (d value) and I/I
0As follows:
Table 1
2θ | d | I/I 0 | 2θ | d | I/I 0 | 2θ | d | I/I 0 |
9.500 | 9.3020 | 21 | 19.200 | 4.6189 | 76 | 24.860 | 3.5786 | 27 |
10.300 | 8.5812 | 33 | 19.600 | 4.5255 | 41 | 25.220 | 3.5283 | 52 |
11.140 | 7.9360 | 66 | 19.900 | 4.4579 | 43 | 25.660 | 3.4628 | 48 |
13.080 | 6.7630 | 35 | 20.180 | 4.3967 | 21 | 26.480 | 3.3632 | 35 |
15.540 | 5.6975 | 43 | 20.840 | 4.2589 | 39 | 27.200 | 3.2758 | 34 |
16.380 | 5.4071 | 21 | 21.700 | 4.0920 | 59 | 28.100 | 3.1729 | 23 |
17.440 | 5.0808 | 31 | 22.500 | 3.9483 | 26 | 29.320 | 3.0436 | 40 |
17.860 | 4.9623 | 41 | 22.860 | 3.8870 | 21 | 30.620 | 2.9173 | 28 |
18.600 | 4.7665 | 28 | 23.360 | 3.8049 | 100 | 30.880 | 2.8933 | 27 |
18.940 | 4.6817 | 53 | 24.220 | 3.6717 | 27 | 33.240 | 2.6931 | 26 |
Process for purification: the 0.5g lamivudine adds 4.5ml methyl alcohol, 10ml acetone, heating for dissolving, cooling crystallization, suction filtration, the dry 0.35g white powder crystal that gets.
Lamivudine IV crystal formation of the present invention uses the Cu-Ka radiation, and the X-ray powder diffraction that represents with 2 θ angles has characteristic peak 9.7 ± 0.2,10.02 ± 0.2,11.24 ± 0.2,11.52 ± 0.2,12.80 ± 0.2,13.10 ± 0.2.
Its infrared analysis data are as follows:
IR(KBr)cm
-1:3340、3235、3075、2927、1647、1613、1493、1404、1357、1289、1198、1108、1053、786
Its fusing point is as follows:
DSC (10 ℃ of heat-up rates/min): a little endothermic melting peak occurs at 119.5 ℃, a sharp-pointed endothermic melting peak occurs again at 176.5 ℃.
Concrete X-ray powder diffraction data are as follows:
Powder X-ray-diffraction: Cu-Ka radiation, the 2 θ angles of this product, spacing (a value) and I/I
0As follows:
Table 2
2θ | d | I/I 0 | 2θ | d | I/I 0 | 2θ | d | I/I 0 |
9.700 | 9.1106 | 18 | 18.600 | 4.7665 | 55 | 24.500 | 3.6304 | 27 |
10.020 | 8.8204 | 20 | 19.520 | 4.5439 | 100 | 24.800 | 3.5871 | 32 |
11.240 | 7.8656 | 38 | 20.380 | 4.3540 | 74 | 25.280 | 3.5201 | 42 |
11.520 | 7.6750 | 28 | 21.140 | 4.1992 | 48 | 25.940 | 3.4320 | 36 |
12.800 | 6.9103 | 19 | 21.560 | 4.1183 | 31 | 26.320 | 3.3833 | 22 |
13.100 | 6.7527 | 23 | 22.000 | 4.0369 | 26 | 27.220 | 3.2734 | 29 |
15.060 | 5.8780 | 38 | 22.260 | 3.9904 | 29 | 27.540 | 3.2361 | 24 |
15.680 | 5.6469 | 35 | 22.760 | 3.9038 | 24 | 29.240 | 3.0517 | 25 |
17.580 | 5.0407 | 30 | 23.240 | 3.8243 | 38 | 31.180 | 2.8661 | 24 |
18.020 | 4.9186 | 27 | 23.580 | 3.7699 | 69 | 31.780 | 2.8134 | 21 |
Process for purification: the 0.6g lamivudine adds 2ml water, 6ml acetone, heating for dissolving, cooling crystallization, suction filtration, the dry 0.4g white powder crystal that gets.
The inventor is studied the chemical stability of two kinds of crystal formations of lamivudine, the investigation condition is high temperature (60 ℃), high humidity (92.5%), strong illumination (4500Lx), investigating index is content and relative substance for investigating index, and contrasts with the listing lamivudine.After placing under various conditions 10 days, two kinds of crystal formation chemical stabilities of lamivudine of the present invention significantly are better than the lamivudine that goes on the market;
Table 3 study on the stability
Table 4 study on the stability
Two kinds of crystal formations of the discovery that the inventor is surprised lamivudine of the present invention have good stability, and drug quality is significant for improving.In addition, lamivudine crystal form of the present invention also has the advantages such as degree of crystallinity is high, size-grade distribution is concentrated, good product mobility, any surface finish.
4, description of drawings
Fig. 1 is the infrared spectrogram of lamivudine III crystal formation;
Fig. 2 is the DSC differential thermal analysis curve of lamivudine III crystal formation;
Fig. 3 is the X-ray powder diffraction spectrogram of lamivudine III crystal formation;
Fig. 4 is the infrared spectrogram of lamivudine IV crystal formation;
The DSC differential thermal analysis curve of Fig. 5 lamivudine IV crystal formation;
Fig. 6 is the X-ray powder diffraction spectrogram of lamivudine IV crystal formation.
5, embodiment
Further describe by the following examples the present invention in detail.But not as limitation of the present invention.
The preparation of embodiment 1 lamivudine III crystal formation
The preparation method: the 0.5g lamivudine adds 4.5ml methyl alcohol, 10ml acetone, heating for dissolving, cooling crystallization, suction filtration, the dry 0.35g white powder crystal that gets.
The preparation of embodiment 2 lamivudine III crystal formations
Get the 1g lamivudine, add 8mL methyl alcohol and 20mL acetone, stir, 60 ℃ of heating 1h filter, and filtrate is left standstill, and is cooled to room temperature, again at 0 ℃ of crystallization 12h, and suction filtration, 50 ℃ of dry 2h get 0.73g white powder crystal.
The preparation of embodiment 3 lamivudine IV crystal formations
The preparation method: the 0.6g lamivudine adds 2ml water, 6ml acetone, heating for dissolving, cooling crystallization, suction filtration, the dry 0.4g white powder crystal that gets.
The preparation of embodiment 4 lamivudine IV crystal formations
Get the 1.2g lamivudine, add 4mL water and 12mL acetone, stir, 55 ℃ of heating 1h filter, and filtrate is left standstill, and is cooled to room temperature, again at 0 ℃ of crystallization 10h, and suction filtration, 50 ℃ of dry 2h get 0.9g white powder crystal.
Claims (4)
1. lamivudine crystal form is characterized in that, is lamivudine IV crystal formation,
Its infrared analysis data are as follows:
IR KBrcm
-1:3340、3235、3075、2927、1647、1613、1493、1404、1357、1289、1198、1108、1053、786
Its fusing point is as follows:
DSC, 10 ℃/min of heat-up rate: a little endothermic melting peak occurs at 119.5 ℃, occur again sharply at 176.5 ℃
Endothermic melting peak,
Concrete X-ray powder diffraction data are as follows:
Powder X-ray-diffraction: Cu-Ka radiation, 2 θ angles, spacing a value and the I/I of this product
0As follows:
2. the preparation method of lamivudine crystal form as claimed in claim 1 is characterized in that, preparation process is as follows: lamivudine adds entry and acetone, heating for dissolving, cooling crystallization, suction filtration, the dry white powder crystal that gets.
3. preparation method as claimed in claim 2 is characterized in that, step is as follows: the 0.6g lamivudine adds 2ml water, 6ml acetone, heating for dissolving, cooling crystallization, suction filtration, the dry 0.4g white powder crystal that gets.
4. the pharmaceutical composition that contains the lamivudine crystal form of claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010254731 CN101993439B (en) | 2009-03-24 | 2009-03-24 | Lamivudine crystal form and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010254731 CN101993439B (en) | 2009-03-24 | 2009-03-24 | Lamivudine crystal form and preparation method thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009101196329A Division CN101531656B (en) | 2009-03-24 | 2009-03-24 | Lamivudine crystal form and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101993439A CN101993439A (en) | 2011-03-30 |
CN101993439B true CN101993439B (en) | 2013-04-24 |
Family
ID=43784254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201010254731 Active CN101993439B (en) | 2009-03-24 | 2009-03-24 | Lamivudine crystal form and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101993439B (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0517145B1 (en) * | 1991-06-03 | 2002-01-30 | Glaxo Group Limited | Crystalline oxathiolane derivatives |
WO2008114279A2 (en) * | 2007-03-19 | 2008-09-25 | Matrix Laboratories Ltd | Novel polymorphs of lamivudine |
-
2009
- 2009-03-24 CN CN 201010254731 patent/CN101993439B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0517145B1 (en) * | 1991-06-03 | 2002-01-30 | Glaxo Group Limited | Crystalline oxathiolane derivatives |
WO2008114279A2 (en) * | 2007-03-19 | 2008-09-25 | Matrix Laboratories Ltd | Novel polymorphs of lamivudine |
Non-Patent Citations (2)
Title |
---|
Harris R.K.等.‘Polymorphism’ in a novel anti-viral agent: Lamivudine.《J. Chem. Soc., Perkin Trans. 2》.1997,(第12期),第2653-2659页. * |
HarrisR.K.等.‘Polymorphism’inanovelanti-viralagent:Lamivudine.《J.Chem.Soc. Perkin Trans. 2》.1997 |
Also Published As
Publication number | Publication date |
---|---|
CN101993439A (en) | 2011-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2007237818B2 (en) | A novel crystalline form of lamivudine | |
CA2494010A1 (en) | Modafinil polymorphic forms | |
WO2008098471A1 (en) | A crystalline form of entecavir, its preparation, pharmaceutical compositions thereof and uses | |
CA3007347A1 (en) | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 | |
JP2020517611A5 (en) | ||
CN102286046B (en) | Preparation method of ribavirin | |
WO2016107289A1 (en) | Method for preparing sofosbuvir crystal form-6 | |
CN104788438A (en) | B crystal form of empagliflozin and preparation of B crystal form | |
CN101531656B (en) | Lamivudine crystal form and preparation method thereof | |
CN101993439B (en) | Lamivudine crystal form and preparation method thereof | |
CN104744464B (en) | Istradefylline crystal formation | |
WO2015111085A2 (en) | Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof | |
CN102093417B (en) | Compound capable of being used for preparing nucleoside phosphoric acid medicaments and preparation method thereof | |
CN101717420B (en) | Novel method for synthesizing uridine | |
CN101928304A (en) | Preparation method of D-ribose | |
CN104829530A (en) | Amorphous ivabradine hydrochloride and preparation method thereof | |
CN102675239A (en) | Method for preparing linezolid crystal form I | |
CN105646585B (en) | A kind of preparation method of (R) 9 [2 (phosphonium mesitoyl methoxy) propyl group] adenine | |
CN103288906A (en) | A 3,5 - bis-O-benzoyl-2-C-methyl-C-methyl C-4 - (1,2,4 - triazolyl) uridine and a synthesis method thereof | |
CN1269797C (en) | Crystalline form of a phenylethanolamine, preparation thereof and pharmaceutical compositions comprising same | |
CN111004300B (en) | Method for preparing Sofosbuvir | |
CN102140124A (en) | Novel synthesis process of capecitabine | |
CN110092807A (en) | A kind of method for preparing azacitidine of high-purity, low ignition residue | |
CN107602613A (en) | A kind of preparation method of (R) 9 [2 (phosphonium mesitoyl methoxy) propyl group] adenine | |
CN1324032C (en) | Novel 9-nitro campotothecin crystal form and medicinal composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent for invention or patent application | ||
CB02 | Change of applicant information |
Address after: 350003, 32 floor, global Plaza, No. 54, 158, Gulou District, Fujian, Fuzhou Applicant after: Fujian Cosunter Pharmaceutical Co., Ltd. Address before: 350003, 32 floor, global Plaza, No. 54, 158, Gulou District, Fujian, Fuzhou Applicant before: Guangshengtang pharmaceutical Industry Co., Ltd. Fujian |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: GUANGSHENGTANG PHARMACEUTICAL INDUSTRY CO., LTD. FUJIAN TO: FUJIAN COSUNTER PHARMACEUTICAL CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |